Association of Higher Daptomycin Dose (7 mg/kg or Greater) with Improved Survival in Patients with Methicillin‐Resistant Staphylococcus aureus Bacteremia
ConclusionTo our knowledge, this is the first comparative effectiveness study of daptomycin doses in patients with MRSA bacteremia. Survival benefits were observed with doses higher than the daptomycin label dose (7 mg/kg or greater) for the treatment of MRSA bacteremia. These data suggest that higher doses than the daptomycin label dose may be preferred over the label dose for improving clinical outcomes in patients with MRSA bacteremia.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - Category: Drugs & Pharmacology Authors: Tristan T. Timbrook, Aisling R. Caffrey, Megan K. Luther, Vrishali Lopes, Kerry L. LaPlante Tags: Original Research Article Source Type: research
More News: Cubicin | Drugs & Pharmacology | Infectious Diseases | MRSA | Staphylococcus Aureus | Study | Superbugs